atopic dermatitis

Rocatinlimab (OX40 blockade) delivers clinically meaningful benefit in moderate-to-severe atopic dermatitis: results from ROCKET-IGNITE and ROCKET-HORIZON

By MedXY 12/01/2025

Two global phase 3 trials show rocatinlimab, an anti‑OX40 therapy, produced statistically significant improvements in EASI‑75 and vIGA‑AD 0/1 at 24 weeks versus placebo with a generally acceptable safety profile.

Dermatology Diabetes & Endocrinology news

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes

By MedXY 11/01/2025

A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-response relation and was stronger in men.

Dermatology Diabetes & Endocrinology news

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

By MedXY 11/01/2025

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

Allergy & Immunology Dermatology news

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

By MedXY 10/28/2025

A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.

Clinical Updates Dermatology news Nursing & care Pediatrics Specialties

Daily Emollient Use in Infants: A Promising Strategy to Prevent Pediatric Atopic Dermatitis

By MedXY 09/03/2025

A large pragmatic trial demonstrates that daily emollient application starting before 9 weeks of age significantly reduces the risk of atopic dermatitis by 24 months in infants not selected for high risk, offering a feasible preventive approach in pediatric dermatology.

Clinical Updates Dermatology news Specialties

JAK Inhibitors and Venous Thromboembolism in Atopic Dermatitis: Clinical Risks and Practice Implications

By MedXY 07/30/2025

JAK inhibitors significantly increase the risk of venous thromboembolism compared to dupilumab and methotrexate in atopic dermatitis, underscoring the need for individualized risk stratification.

Clinical Updates Dermatology Specialties

JAK Inhibitors and Thromboembolic Risk in Atopic Dermatitis: A Comparative Safety Signal

By MedXY 07/29/2025

A large real-world cohort study finds JAK inhibitors increase risk of venous thromboembolism versus dupilumab and methotrexate in atopic dermatitis, highlighting the need for individualized therapy.